Evaluation and Comparison of the Growth Rate of Pancreatic Cancer Patient-derived Organoids

Evaluation and Comparison of the Growth Rate of Pancreatic Cancer Patient-derived Organoids Generated From Matched Fine Needle Aspirations (FNA) and Fine Needle Biopsies (FNB)

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03990675

Enrollment

Registered

2019-06-19

Start date

2018-12-01

Completion date

2022-08-01

Last updated

2019-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreas Cancer

Brief summary

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive forms of cancer. Despite advances in the understanding of the mechanisms underlying PDAC pathogenesis, the impact on patient benefit is lagging. As a result, new model systems are being developed and used to fill this gap with the hope of translation into improved diagnostics and therapeutics. Organoids represent a powerful tool for research with the capacity to be applied to many key aspects of pancreatic tissue pathology. 3D organoids can be generated from endoscopic fine-needle aspiration or fine needle biopsy samples. In this study, we will evaluate and compare the growth rate of pancreatic cancer patient-derived organoids generated from matched fine needle Aspirations (FNA) and fine needle biopsies (FNB).

Interventions

PROCEDUREFNA, FNB

Endoscopic ultrasound guided fine needle aspiration, Endoscopic ultrasound guided fine needle biopsy

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with indication for EUS-guided FNA or FNB of a suspected pancreatic malignancy

Exclusion criteria

* \< 18 years * patients unable to give consent

Design outcomes

Primary

Measure	Time frame	Description
Growth rate	4 days	Organoid growth will be determined using bi-weekly measurements by phase-contrast microscopy calculating the total organoid area as well as individual organoid size. In addition, growth rates will be determined using the cell glow assay (Promega) over a time-course of 4 days. Furthermore, the mean passaging time will be calculated after 5 passages.

Countries

Germany

Contacts

Primary ContactChristoph Schlag, MD

christoph.schlag@mri.tum.de+49 89 4140 9357

Backup ContactMaximilian Reichert, MD

maximilian.reichert@tum.de+49 89 4140 9454

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026